Seasonal Influenza Vaccines - US Drug Forecast and Market Analysis to 2025
Influenza, often referred to as the flu, is an acute infection caused by one of the three closely related viruses, designated as influenza Type A, B, and C. The infection’s rapid onset and potential for high morbidity and mortality, particularly in high-risk patient populations such as the elderly and young children, make prompt and effective treatment with antiviral medication very difficult. For these reasons, prophylactic vaccination is the preferred intervention for seasonal influenza.
The US will experience solid growth in seasonal influenza vaccine sales during the forecast period, and this growth will be driven by a significant shift in the market share distribution of the different vaccine types. The US market will experience the largest nominal change of any country in the 7MM.
Overview of Seasonal Influenza Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for the top drugs in the US from 2015-2025.
Analysis of the impact of key events as well the drivers and restraints affecting the US Seasonal Influenza Vaccines market.
Reasons to buy
Understand and capitalize by identifying products that are most likely to ensure a robust return
Stay ahead of the competition by understanding the changing competitive landscape for Seasonal Influenza Vaccines.
Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
Make more informed business decisions from insightful and in-depth analysis of drug performance
Obtain sales forecast for drugs from 2015-2025 in the US.